|Application ||WB, E|
|Calculated MW||55760 Da|
|Antigen Region||466-494 aa|
|Other Names||Plexin domain-containing protein 1, Tumor endothelial marker 3, Tumor endothelial marker 7, PLXDC1, TEM3, TEM7|
|Target/Specificity||This PLXDC1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 466-494 amino acids from the C-terminal region of human PLXDC1.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||PLXDC1 Antibody(C-term) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Plays a critical role in endothelial cell capillary morphogenesis.|
|Cellular Location||Isoform 1: Cell membrane; Single-pass type I membrane protein. Cell junction, tight junction. Note=Localized predominantly at the tight junctions of vascular endothelial cells and to a lesser extent at the luminal surface of vascular endothelial cells Isoform 3: Secreted.|
|Tissue Location||Detected in endothelial cells from colorectal cancer, and in endothelial cells from primary cancers of the lung, liver, pancreas, breast and brain. Not detectable in endothelial cells from normal tissue. Expressed in fibrovascular membrane with increased expression in individuals with proliferative diabetic retinopathy.|
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abgent to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Plays a critical role in endothelial cell capillary morphogenesis.
Rose, J. Phd, et al. Mol. Med. (2010) In press :
Halder, C., et al. Anticancer Res. 29(11):4317-4322(2009)
Yamaji, Y., et al. Invest. Ophthalmol. Vis. Sci. 49(7):3151-3157(2008)
Fuchs, B., et al. Gene 399(2):137-143(2007)
Nanda, A., et al. Cancer Res. 64(23):8507-8511(2004)
If you have used an Abgent product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at firstname.lastname@example.org.